Logo Image
News|Articles|March 11, 2024

Measuring Speaker Campaign Effectiveness

Author(s)Pharmagin

Sales and marketing effectiveness of speaker programs is often one of the least understood aspects in the industry. Yet, pharma brands spent over $12.5 billion in 2022 to engage and influence with HCP-to-HCP activities. CMS’s Open Payments data is an overlooked tool to get greater visibility and create more strategic opportunities—while also enriching compliance. This paper explores how to filter and pinpoint critical data sets using browser-based technology to gain marketing insights from this data and measure competitiveness.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more